




ILUVIEN[®]

Administration guide

ILUVIEN[®]
Fluocinolone Acetonide
190 micrograms intravitreal
implant in applicator



ILUVIEN® is an intravitreal implant providing sustained-release delivery of a corticosteroid directly in the vitreous cavity for up to 36 months. Each implant contains 190 micrograms of fluocinolone acetonide. The implant is a tiny tube measuring approximately 3.5 mm x 0.37 mm in size and is administered via a custom applicator with a 25-gauge needle.



Therapeutic Indications

ILUVIEN is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies.

ILUVIEN is indicated for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

Contraindications

An intravitreal implant with ILUVIEN is contraindicated in the presence of pre-existing glaucoma or active or suspected ocular or periocular infection including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.

ILUVIEN is contraindicated in patients with infectious uveitis and/or hypersensitivity to the active substance or to any of these excipients: polyvinyl alcohol, polyimide tube, silicone adhesive.

Posology

The recommended dose is one ILUVIEN implant in the affected eye. Administration in both eyes concurrently is not recommended.

Each ILUVIEN implant releases fluocinolone acetonide for up to 36 months.

Diabetic Macular Oedema

An additional implant may be administered after 12 months if the patient experiences decreased vision or an increase in retinal thickness secondary to recurrent or worsening diabetic macular oedema.

Retreatments should not be administered unless the potential benefits outweigh the risks.

Only patients who have been insufficiently responsive to prior treatment with laser photocoagulation or other available therapies for diabetic macular oedema should be treated with ILUVIEN.

Non-Infectious Uveitis Affecting the Posterior Segment

There are no data available to support the retreatment of patients with an additional implant when used for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment (NIU-PS) of the eye.

Paediatric population

There is no relevant use of intravitreally administered fluocinolone acetonide in the paediatric population in diabetic macular oedema (DMO).



The safety and efficacy in uveitis in the paediatric population has not been established.

Special populations



No dosage adjustments are necessary in elderly patients, or those with renal or hepatic impairment.

Preparing the patient for the intravitreal injection of ILUVIEN


Treatment with ILUVIEN is for intravitreal use only and should be administered by an ophthalmologist experienced in intravitreal injections. The intravitreal injection procedure should be carried out under controlled aseptic conditions, which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anaesthesia and a broad-spectrum microbicide should be given prior to the injection.



Preparation of the ILUVIEN applicator



ILUVIEN injection procedure




8

The optimal placement of the implant is inferior to the optic disc and posterior to the equator. This can be achieved by directing the needle toward the lower aspect of the optic disc. Measure 4 millimetres inferotemporal from the limbus with the aid of calipers.




9

Maintaining the injector tip above the horizontal plane, carefully remove the protective cap from the needle and inspect the tip to ensure it is fit for injecting.



10

Gently displace the conjunctiva so that after withdrawing the needle, the conjunctival and scleral needle entry sites will not align. Care should be taken to avoid contact between the needle and the lid margin or lashes.



11

Insert the needle in the eye. To release the implant, while the button is in the UP position, slide the button forward to the end and remove the needle. Note: Ensure the button reaches the end and stops before removing the needle.



12

Remove the lid speculum and perform indirect ophthalmoscopy to verify the placement of the implant, adequate central retinal artery perfusion, and absence of any other complications.

Aftercare: Follow-up after the ILUVIEN injection



Following intravitreal injection, indirect ophthalmoscopy examination in the quadrant of injection should be performed to ensure successful placement. Scleral depression may enhance visualisation of the implant.

Examination should include a check for perfusion of the optic nerve head immediately after the injection. Immediate intraocular pressure measurement may be performed at the discretion of the ophthalmologist.

Following the procedure, patients should be monitored for potential complications such as endophthalmitis, increased intraocular pressure, retinal detachments, and vitreous haemorrhages or detachments and ocular hypotony (observed up to 8 days post treatment). Biomicroscopy with tonometry should be performed between two and seven days after the implant injection.

Thereafter it is recommended that patients are monitored at least quarterly for potential complications, due to the extended duration of release of fluocinolone acetonide of approximately 36 months.

Adverse Events

Diabetic Macular Oedema

In the phase 3 studies for DMO, 38.4% of subjects treated with ILUVIEN required intraocular pressure (IOP)-lowering medication and 4.8% required IOP-lowering surgeries. The use of IOP-lowering medication was similar in subjects who received two or more treatments with ILUVIEN.

The incidence of cataract in phakic subjects was approximately 82% in ILUVIEN treated subjects and 50% in sham treated subjects in the phase 3 clinical trials. 80% of phakic subjects treated with ILUVIEN required cataract surgery by year 3.

Non-Infectious Uveitis Affecting the Posterior Segment

In the 36 month study for NIU-PS, 42.5% of subjects treated with ILUVIEN required intraocular pressure (IOP)-lowering medication and 5.7% required IOP-lowering surgeries versus 11.9% in the sham injection group.

The incidence of cataract in the total study population of subjects was approximately 42.5% in Fluocinolone acetonide treated subjects and 23.8% in sham treated subjects. 73.8% of phakic subjects treated with fluocinolone acetonide required cataract surgery by year 3.

The following undesirable effects were assessed to be treatment-related:

Infections and infestations	<u>Uncommon</u> : endophthalmitis
Nervous system disorders	<u>Uncommon</u> : headache
Eye disorders	<p><u>Very Common</u>: cataract, increased intraocular pressure</p> <p><u>Common</u>: glaucoma, retinal detachment, optic disc haemorrhage*, vitreous haemorrhage, reduced visual acuity, visual field defect*, macula fibrosis*, conjunctival haemorrhage blurred vision*, hypotony of eye*, vitreous floaters, anterior chamber cells*, vitreous opacities*, foreign body sensation in eyes*, dry eye*, photopsia*, eye pain.</p> <p><u>Uncommon</u>: retinal vascular occlusion, optic nerve disorder, maculopathy, optic atrophy, conjunctival ulcer, iris neovascularisation, retinal exudates, vitreous degeneration, vitreous detachment, choroidal detachment*, corneal erosion*, corneal deposits, posterior capsule opacification, iris adhesions, blepharospasm*, eye oedema*, ocular hyperaemia, sclera thinning, eye discharge, eye pruritus</p>
Injury, poisoning and procedural complications	<u>Uncommon</u> : extrusion of implant, implant in line of sight, procedural complication, procedural pain
Surgical and medical procedures	<p><u>Very Common</u>: cataract operation</p> <p><u>Common</u>: trabeculectomy, glaucoma surgery, vitrectomy, trabeculoplasty</p> <p><u>Uncommon</u>: removal of extruded implant from sclera</p>
General disorders and administration site conditions	<u>Uncommon</u> : Device dislocation (implant migration)

* Observed only in patients with Uveitis

Special warnings and precautions

Intravitreal injections have been associated with endophthalmitis, elevation or decrease in intraocular pressure, retinal detachments and vitreous haemorrhages or detachments.

Patients should be instructed to report without delay any symptoms suggestive of endophthalmitis.

Patient monitoring within 2 to 8 days following the injection may permit early identification and treatment of ocular infection, increase or decrease in intraocular pressure or other complications. It is recommended that intraocular pressure be monitored at least quarterly thereafter.

In the phase 3 studies for NIU-PS patients treated with fluocinolone acetonide developed hypotony, which started within days of treatment, with many on Day 1 and mostly resolving within 1 week of onset. Patient monitoring of increased or decreased IOP immediately after and within two to eight days following the injections is recommended.

In the treatment of patients with uveitis, it is very important to exclude possible infective causes of uveitis prior to commencing therapy with ILUVIEN.

There is a potential for implants to migrate in to the anterior chamber, especially in patients with posterior capsular abnormalities, such as tears. This should be taken into consideration when examining patients complaining of visual disturbance after treatment.

Use of intravitreal corticosteroids may cause cataracts, increased intraocular pressure, glaucoma, and may increase the risk of secondary infections.

The safety and efficacy of ILUVIEN administered to both eyes concurrently have not been studied. It is recommended that the implant is not administered to both eyes at the same visit. Concurrent treatment of both eyes is not recommended until the patient's systemic and ocular response to the first implant is known.

In the event of intraocular pressure increases that do not respond to intraocular pressure-lowering medications or intraocular pressure lowering procedures, the ILUVIEN implant can be removed by vitrectomy.



This guide does not intend to provide guidance on management of adverse events. The assessment and management of any adverse events should be made on an individualised basis by a qualified ophthalmologist.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Alimera Sciences Limited (telephone: 0800 148 8274) pvalimerasciences@alimerasciences.com

Alimera Sciences Limited

Royal Pavilion
Wellesley Road
Aldershot
Hampshire
GU11 1PZ
United Kingdom

For medical enquiries please email:

medicalinformation@alimerasciences.com

or call:

0800 0191 253



© 2019 Alimera Sciences Limited

Date of preparation: June 2019; UK-ILV-MMM-0410. v4.0

MHRA Approval: 06/2019

References:

1. ILUVIEN, Summary of Product Characteristics.
2. Campochiaro PA, Brown DM, et al. Ophthalmology 2012; 119: 2125-2131.